Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 11
Phase 24

Trial Status

Completed2
Terminated2

Role Distribution

Principal Investigator4
PI Rate100%

Activity Timeline

Clinical Trials (4)

NCT00276159Phase 2Terminated
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic Leukemia+3 more
Principalinvestigator
NCT00319748Phase 2Completed
Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
Breast CancerCervical CancerEndometrial Cancer+1 more
Principalinvestigator

Research Network

Collaboration Network

3 collaborators·2 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Jeffrey Miller, MD

Masonic Cancer Center, University of Minnesota

Similar
8 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteBreast CancerPrecursor Cell Lymphoblastic Leukemia-Lymphoma+2 more

Worked with same sponsors:

Masonic Cancer Center, University of MinnesotaPfizer
Collaborated on 1 trial
Similarity Score54%

Melissa A. Geller, MD

Masonic Cancer Center, University of Minnesota

Moderately Similar
5 trials

Shared therapeutic areas:

Ovary CancerEndometrial CarcinomaBreast Cancer+1 more

Worked with same sponsors:

Masonic Cancer Center, University of MinnesotaPfizer
Collaborated on 1 trial
Similarity Score44%

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

Multiple MyelomaLeukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-Cell+3 more
Similarity Score18%

John D. Hainsworth, MD

SCRI Development Innovations, LLC

Related
26 trials

Shared therapeutic areas:

Lymphoma, Non-HodgkinBreast CancerMultiple Myeloma+2 more
Similarity Score15%

Steven A Rosenberg, M.D.

National Cancer Institute (NCI)

Related
32 trials

Shared therapeutic areas:

Breast CancerOvary CancerCancer of the Uterine Cervix+1 more
Similarity Score12%

Francesco Perrone, M.D., Ph.D.

National Cancer Institute, Naples

Related
13 trials

Shared therapeutic areas:

Ovary CancerPrecursor Cell Lymphoblastic Leukemia-LymphomaCancer of the Uterine Cervix+1 more
Similarity Score12%

Lei Li, M.D.

Peking Union Medical College Hospital

Related
46 trials

Shared therapeutic areas:

Cancer of the Uterine CervixEndometrial CarcinomaOvary Cancer
Similarity Score9%

Zhenfeng Zhang, MD, PhD

Second Affiliated Hospital of Guangzhou Medical University

Related
21 trials

Shared therapeutic areas:

Breast CancerCancer of the Uterine CervixOvary Cancer
Similarity Score9%

Hagop Youssoufian, MD

Verastem, Inc.

Related
20 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellOvary Cancer
Similarity Score6%

Areej El-Jawahri, MD

Massachusetts General Hospital

Related
21 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteMultiple Myeloma
Similarity Score6%

Publications (0)

No publications found for this investigator.

Clinical Trials (4)

Showing 4 of 4 trials

NCT00276159Phase 2PrincipalInvestigator

Study of Immune Response Modifier in the Treatment of Hematologic Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic Leukemia+3 more
Terminated
NCT00303667Phase 1/2PrincipalInvestigator

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

Acute Myelogenous Leukemia
Completed
NCT00319748Phase 2PrincipalInvestigator

Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers

Breast CancerCervical CancerEndometrial Cancer+1 more
Completed
NCT00376805Phase 2PrincipalInvestigator

Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer

Breast Cancer
Terminated

All 4 trials loaded